Currently, a phase I clinical trial is underway to assess the tolerability of vorinostat in AD patients [71] and whilst modifications in microglial-mediated immune functions are not the primary endpoint of such trials, if found to be tolerable this anti-inflammatory contribution could be beneficial in limiting microglial-mediated neurodegeneration through a PU.1-mediated mechanism. Here, SPI1 is linked to Alzheimer disease.